A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

Phase 1 Not yet recruiting 68 enrolled Zhejiang Wenda Pharma Technology LTD.

RandomizedSequentialDouble-blindOther

Summary

This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed

Timeline

Start: 2025-06-30
Primary completion: 2025-10-31
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WD-910	Unknown	—	Oral

Indications

No indication recorded.